Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 1997

View Archived Issues

NK1 antagonist effective in rat model of focal cerebral ischemia

Attenuation of cyclophosphamide-induced bladder damage in animals by GR-203040

Inflazyme contracts Inveresk Research for IND support

New orally active immunosuppressant for combination with ciclosporin

Additional results for Bradycor in traumatic brain injury

Kosan receives NIH grant for macrolide antibiotic development

Schering-Plough seeks approval for pediatric indication of Intron A

Novastan granted priority review status by FDA

Preliminary results reported for RMP-7/carboplatin

Promising phase II results for Genzyme Transgenics' rhATIII

Pharmacia & Upjohn's urinary incontinence treatment approved in Sweden

Agents useful for BPH from Pfizer

Warner-Lambert/CoCensys develop neuroprotective agents

Osteoprotegerin: new polypeptide for bone diseases

Ribi seeks approval for melanoma vaccine in Canada

Ethnic differences in codeine's efficacy/side effects

Copaxone approved in Canada

SB-204269, an anticonvulsant with a unique mechanism of action

Resveratrol found in edible peanuts

RPR submits NDA for novel antibiotic

Nepicastat: a novel dopamine-beta-hydroxylase inhibitor for CHF

GSH prevents cisplatin-induced toxicity

Treatment for preleukemic disorder from Milkhaus enters phase III

Effects of AE-0047 on lipid profiles

CDR Therapeutics and CellGenEx merge to form Xcyte Therapies

(S)-(-)-OSU-6162 effective in monkey model of Parkinson's disease

Tolmetin eyedrop formulation evaluated in rabbits

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...